Trypan Blue Versus Brillant Blue for Epiretinal Membranes

Idiopathic Epiretinal Membranes Clinical Trial

Official title:

Membranepeeling With Trypan Blue Versus Membranpeeling With Brillant Blue for Patients With Idiopathic Epiretinal Membranes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00757380
• Other study ID #: FR-4-CI-2008
• Status: Completed
• Phase: N/A
• First received: September 21, 2008
• Last updated: January 24, 2016
• Start date: July 2008
• Est. completion date: August 2015

Study information

• Verified date: January 2016
• Source: The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
• Contact: n/a
• Is FDA regulated: No
• Health authority: Austria: Ethikkommission
• Study type: Interventional

Clinical Trial Summary

Membraneppeling alone versus Membranepeeling with Membrane Limitans Interna Pelling using two different Dyes for Epiretinal Membrane Surgery.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: August 2015
• Est. primary completion date: August 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

• Idiopathic eperetinal membranes

• Phakic or pseudophakic eyes

• Age over 60 years

Exclusion Criteria:

• Secondary epiretinal membranes

• Severe ocular pathologies

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Epiretinal Membrane
• Idiopathic Epiretinal Membranes

Intervention

Procedure:
• Trypan Blue
Membranepeeling with TB
• Brillant Blue
Membranepeeling and membrana limitans interna peeling with BB

Locations

Country	Name	City	State
Austria	The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery	Vienna

Sponsors (1)

Lead Sponsor	Collaborator
The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery

Country where clinical trial is conducted

Austria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Visual acuity		3 months	Yes
Secondary	Microperimetry optical coherence tomographie questionnaire (metamorphopsien)		3 months	Yes